A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)
- Conditions
- Colitis, Ulcerative
- Interventions
- Drug: Matching Placebo
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 112
- Registration Number
- NCT04630028
- Locations
- π΅π±
WIP Warsaw IBD Point Profesor Kierkus, Warszawa, Poland
πΊπΈCook Childrens Medical Center, Fort Worth, Texas, United States
π©πͺUniversitatsklinikum Essen, Essen, Germany
A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease
- Conditions
- Alzheimer DiseaseCognitive DysfunctionDementia
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 523
- Registration Number
- NCT04619420
- Locations
- π§πͺ
UCL Hopital Saint-Luc, Brussels, Belgium
π§πͺUZ Antwerpen, Edegem, Belgium
π§πͺUniversitair Ziekenhuis Gent, Gent, Belgium
A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT04616677
- Locations
- πΊπΈ
AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company, Knoxville, Tennessee, United States
πΊπΈOrlando Clinical Research Center, Orlando, Florida, United States
A Study of Intravenous Formulation of Guselkumab Using Prefilled Syringes and Final Vialed Product in Healthy Participants
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 140
- Registration Number
- NCT04617691
- Locations
- π©πͺ
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 2
- First Posted Date
- 2020-11-02
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 13
- Registration Number
- NCT04611971
- Locations
- π§πͺ
Clinical Pharmacology Unit, Merksem, Belgium
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Conditions
- Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 153
- Registration Number
- NCT04609826
- Locations
- π«π·
Centre Hospitalier Universitaire (CHU) de Bordeaux Hopital HautLeveque Centre Francois Magendie, Pessac, France
π«π·CHU de Nice Hopital de l Archet, Nice, France
π«π·Institut Universitaire du Cancer Toulouse Oncopole, Toulouse cedex 09, France
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
- Conditions
- Advanced Solid Malignancies
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 159
- Registration Number
- NCT04606381
- Locations
- π¨π¦
University Health Network, Toronto, Ontario, Canada
πΊπΈCommunity Health Network, Indianapolis, Indiana, United States
π¬π§Royal Marsden Hospital, Sutton, United Kingdom
Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer
- Conditions
- Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT04599712
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 477
- Registration Number
- NCT04599855
- Locations
- πΊπΈ
University of Chicago, Chicago, Illinois, United States
πΊπΈOhio State University, Columbus, Ohio, United States
πΊπΈLehigh Center for Clinical Research, Allentown, Pennsylvania, United States
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT04589026
- Locations
- π§πͺ
Clinical Pharmacology Unit, Merksem, Belgium